ISPOR 2024 Atlanta

Share on:

Sunday, May 5 - Wednesday, May 8, 2024

Conference website

Georgia World Congress Center
285 Andrew Young International Blvd
Atlanta, GA 30313
United States

HEOR: A Transformative Force for Whole Health

Our team of experts is looking forward to this year's ISPOR conference in Atlanta - the birthplace of Coca-Cola, the home of the world's largest drive-in restaurant (The Varsity), the city with over 70 streets named "Peachtree," and the place you'll be able to take in our research and visit with our world-renowned research experts.

Take a look below to see what research we'll be bringing and which researchers will be attending.

Preconference Short Courses | May 5
All times are listed in Eastern Time Zone (ET)

May 5

8:00 am-12:00 pm

Advanced patient-reported outcomes. Gnanasakthy A, Crawford R, Qin S, Rockwood N, Doward L.

May 5

1:00 pm-5:00 pm

Estimating health-state utility for economic models in clinical trials and real-world studies. Wolowacz S, Lloyd A, Doward L, Hawe E.

Sessions our researchers are moderating

May 6, 5:00-6:00 pm

Case studies

Oncology and rare disease

Sorrel Wolowacz, PhD, moderating

May 7, 10:15-11:15 am

Podium session

Modeling for HTA

Will Herring, PhD, moderating

May 7, 1:45-2:45 pm

Concurrent breakout session 5

Value assessment and reimbursement of early treatment for prevention in chronic progressive diseases: are traditional approaches up to the task? Herring WL, Cole A, Phelps CE, Jiao B.

Will Herring, PhD, moderating

Poster session 1 | May 6, 10:30-1:30 am

EE104

Value assessment of emerging treatments for nonalcoholic steatohepatitis: lessons from Institute for Clinical and Economic Review evaluations. doi: 10.1016/j.jval.2024.03.403Herring WL, Wittrup-Jensen V, Fox L.

EE106

Cost-effectiveness analysis of belimumab for the treatment of adults with active lupus nephritis in China. doi: 10.1016/j.jval.2024.03.405Wu B, He X, Tang Z, Martin A, Bracher M, Guo N, Campbell K.

Poster session 2 | May 6, 3:30-6:30 pm

MT16

What is the medical technology HTA process in Japan? doi: 10.1016/j.jval.2024.03.1554Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L.

PCR76

Exploring the content and psychometric validity of clinical outcome assessments in renal cell carcinoma versus the patient reported symptoms and impacts. doi: 10.1016/j.jval.2024.03.1955Petit I, Eliasson L, Romero B, Patel C, Di Rosa A, Quinn J.

Poster session 3 | May 7, 10:30 am-1:30 pm

CO96

Evidence gap analysis of the burden of illness and treatment of thyroid eye disease. doi: 10.1016/j.jval.2024.03.184Gildea L, Arvin-Berod C, Heyes A, Heyerick A, Urdaniz E, Vainilovich Y, Trainor L, Densmore D.

EE281

Cost-effectiveness of every two month Cabotegravir Long-Acting (CAB-LA) for Pre-exposure Prophylaxis (PrEP) compared with daily oral Tenofovir Disoproxil Fumarate (TDF)/ emtricitabine (FTC) as PrEP to prevent HIV-1 UK. doi: 10.1016/j.jval.2024.03.580O'Brien P, Campbell K, Anderson SJ, Cornic L, Davis A, Schroeder M.

EPH140

Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins in cancer associated thrombosis. doi: 10.1016/j.jval.2024.03.969Yande S, Johnson ML, Aparasu RR, Toale K, Wanat M.

MT26

HTA requirements for medical technologies in Canada. doi: 10.1016/j.jval.2024.03.1564Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L.

PCR121

Optimizing drug value and access using implementation science. doi: 10.1016/j.jval.2024.03.2000Bonner C, Pilar M, Jacobs S, Samsell B, Hollis K.

Poster session 4 | May 7, 3:30-6:30 pm

PCR176

Preferences for a combination influenza and COVID-19 vaccine: results from a threshold technique study with consumers in the United Kingdom. doi: 10.1016/j.jval.2024.03.2055Poulos C, McMichael A, Kent C, Rudin D, Buck P, Ghaswalla P, Mehta D.

RWD138

Evidence gap analysis of the burden of illness and treatment of myasthenia gravis. doi: 10.1016/j.jval.2024.03.1792Copley-Merriman K, Miller-Wilson LA, Costello J, Schwinn J, Edwards Y.

SA69

Enhancing the value and usefulness of data extracted from an economic systematic literature review. doi: 10.1016/j.jval.2024.03.1916Miles L, Mauskopf J.

Poster session 5 | May 8, 9:00-11:30 am

EE435

Hospitalization costs of common grade 3/4 adverse events associated with oncology treatments in the United States. doi: 10.1016/j.jval.2024.03.730Graham CN, Erbe AW.

EE440

Cost-effectiveness of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years with cardiopulmonary diseases in the United States. doi: 10.1016/j.jval.2024.03.735Singer D, La E, Graham J, Grace M, Poston S, Molnar D.

EE443

Work loss associated with adult vaccinations in pharmacy and healthcare professional office settings in the United States. doi: 10.1016/j.jval.2024.03.738La E, Sweeney C, Davenport E, Bunniran S.

EE471

Budget impact of pirtobrutinib for patients with Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the United States (US). doi: 10.1016/j.jval.2024.03.2236Winfree KB, Zhang KH, Muehlenbein CE, Panjic EH, Ale-Ali A, Graham CN.

EE495

A targeted literature review of lung function decline in idiopathic pulmonary fibrosis to improve survival predictions in cost-effectiveness analyses. doi: 10.1016/j.jval.2024.03.2259Dong OM, Herring W, Chopra P, Elpers B, Johannesen K.

PCR228

Healthcare provider preferences for attributes of influenza vaccines in the United States: results from a discrete-choice experiment study. doi: 10.1016/j.jval.2024.03.2106Poulos C, McMichael A, Kent C, Rudin D, Buck P, Ghaswalla P, Mehta D.

PCR265

Measurement of health insurance literacy and identification of its correlates among working-age cancer survivors in the US. doi: 10.1016/j.jval.2024.03.2143Korgaonkar S, Bentley J, Holmes E, Barnard M, Ramachandran S, Chang Y, Yang Y.

RWD164

Evidence gap analysis of the burden of disease in thyroid eye disease. doi: 10.1016/j.jval.2024.03.2461Masaquel C, Miller-Wilson LA, D'Souza V, Schwinn J, Mina-Osorio P.

Value assessment and reimbursement of early treatment for prevention in chronic progressive diseases

Value assessment and reimbursement of early treatment for prevention in chronic progressive diseases: Are traditional approaches up to the task?

Enhancing the Usefulness of Economic Systematic Literature Review Data

Enhancing the Value and Usefulness of Data Extracted from an Economic Systematic Literature Review

Health-State Utility Estimates for Economic Models

If you have questions about collecting health-state utility estimates for economic models, register for this course at ISPOR 2024.

Meet up with our experts

We have many staff members who serve in leadership roles for ISPOR. Here are those who are leadership in Special Interest Groups.

Sorrel Wolowacz, PhD - Member Engagement Co-chair, Oncology SIG
Chris Graham, MS - Member Engagement Co-chair, Oncology SIG
Lynda Doward, MRes - Co-chair, Clinical Outcomes Assessment SIG
Emma Hawe, MSc - Chair of Statistical Methods in HEOR SIG & Stats SIG Chair
Christine Poulos, PhD - Co-chair, Health Preference Research Interest Group

Chase Brown, MS

Business Development Specialist

T. Michelle Brown, PhD

Executive Director, Patient-Centered Outcomes Assessment

Jarrod Bullard, PhD

Senior Research Data Scientist

Michael Chance

Michael L Chance, BA

Director, Business Development

Kati Copley-Merriman, MBA

Vice President, Market Access and Outcomes Strategy

Rebecca Crawford, MA

Director, Patient-Centered Outcomes Assessment

Keith Davis, MA

Head, Health Economics

Olivia Dong, PhD

Associate Director, Health Economics

Lynda Doward, MRes

VP, European Head Patient-Centered Outcomes Assessment

Stephanie Earnshaw, PhD

Senior Vice President, Health Economics

Senior Director, Technology Leader

David Fontaine, BS

Director, Business Development

Lindsey Fox, PhD

Senior Research Health Economist

Ari Gnanasakthy, MBA, MSc

Principal Scientist, Patient-Centered Outcomes Assessment

Ravi Goyal, PhD

Senior Director, Health Economics

Mei Grace

Senior Research Health Economist

Jonathan Graham, BS

Senior Director, Health Economics

Amy Greenblatt, PhD, RN

Senior Research Scientist, Patient-Centered Outcomes Assessment

Louise Hartley, PhD

Senior Director, Evidence Synthesis and Statistics

Head, Data Analytics and Design Strategy

William L Herring, PhD

Executive Director, Health Economics

Kelly Hollis, MBA

Vice President, Surveys and Observational Studies

Candace Howze, BA

Marketing Specialist

Siddharth Karanth, DrPH

Director, Health Economics

Shahnaz Khan, MPH

Vice President, Market Access and Outcomes Strategy

Alisha Krumbach, PharmD

Senior Associate, Market Access and Outcomes Strategy

Kate Lothman, BA

Director, Medical Writing, Editing, and Design Services

Lori McLeod, PhD

Vice President, Patient-Centered Outcomes Assessment

LaStella Miles, MS

Associate Director, Health Economics

Margaret Mordin, MS

Vice President, Market Access and Outcomes Strategy

Mark Morrison, BS

Director, Business Development

Elizabeth Myer, PhD

Senior Research Scientist, Patient-Centered Outcomes Assessment

Kelley Myers, PhD

Senior Economist

Vice President, Biostatistics

Christine Poulos, PhD

Senior Economist and Vice President, Health Preference Assessment

Shanshan Qin, PhD

Director, Psychometrics, Patient-Centered Outcomes Assessment

Chelsea Richards, BS

Business Development Specialist

Nicholas Rockwood

Nicholas Rockwood, PhD

Senior Psychometrician, Patient-Centered Outcomes Assessment

Mike Tanner, BS

Director, Business Development

Daniel Tran, PharmD

Senior Associate, Market Access and Outcomes Strategy

Peter Wirth, BS

Vice President, Business Development

Sorrel Wolowacz, PhD

Head, European Health Economics

Soham Yande, PhD

Senior Health Outcomes Scientist, Health Economics